Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

NCT01685814 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

406

Enrollment

OTHER

Sponsor class

Conditions

Previously Untreated Symptomatic Multiple Myeloma

Interventions

DRUG: Lenalidomide, Bortezomib
BIOLOGICAL: autologous stem cell transplant
BIOLOGICAL: allogeneic stem cell transplant

Sponsor

Wuerzburg University Hospital

Collaborators

[object Object]
[object Object]